Surrogacy of intermediate clinical endpoints for overall survival in BCG-naive high-risk non-muscle-invasive bladder cancer. Scilipoti P, Slusarczyk A, Subiela JD, Longoni M, et al. World J Urol 2026;44:721.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Scilipoti P, Slusarczyk A, Subiela JD, Longoni M, et al. Surrogacy of intermediate clinical endpoints for overall survival in BCG-naive high-risk non-muscle-invasive bladder cancer. World J Urol 2026;44:721.
PMID: 42823574